A5006021629- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiac Valve Diseases and Treatments
- Acute Ischemic Stroke Management
- Cardiac Arrest and Resuscitation
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Meta-analysis and systematic reviews
- Vascular Procedures and Complications
- Cardiovascular Function and Risk Factors
- Health Sciences Research and Education
- Cerebrovascular and Carotid Artery Diseases
- Lipoproteins and Cardiovascular Health
- Hemodynamic Monitoring and Therapy
- Mechanical Circulatory Support Devices
- Statistical Methods in Clinical Trials
- Cardiac Health and Mental Health
University of British Columbia
2015-2024
Hamilton Health Sciences
2012-2024
Universidad Autónoma de Madrid
2024
Radboud University Medical Center
2024
Christ Hospital
2024
Health Net
2024
Radboud University Nijmegen
2024
Population Health Research Institute
2016-2024
Sorbonne Université
2024
St Mary's Hospital
2008-2024
We performed a randomized, double-blind, placebo-controlled trial in 555 patients with unstable angina who were hospitalized coronary care units. Patients received one of four possible treatment regimens: aspirin (325 mg times daily), sulfinpyrazone (200 both, or neither. They entered into the within eight days hospitalization and treated followed for up to two years (mean, 18 months). The incidence cardiac death nonfatal myocardial infarction, considered together, was 8.6 per cent groups...
In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces risk cardiovascular death or infarction. Whether PCI nonculprit lesions further such events is unclear.
During primary percutaneous coronary intervention (PCI), manual thrombectomy may reduce distal embolization and thus improve microvascular perfusion. Small trials have suggested that improves surrogate clinical outcomes, but a larger trial has reported conflicting results.We randomly assigned 10,732 patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI to strategy of routine upfront versus alone. The outcome was composite death from cardiovascular causes, recurrent...
Despite increasing incidence and morbidity, little evidence exists to inform the best management approach in childhood empyema.To compare chest drain with intrapleural urokinase primary video-assisted thoracoscopic surgery (VATS) for treatment of empyema.Children were prospectively randomized receive either percutaneous or VATS. The outcome was number hospital days after intervention. Secondary end points days, total stay, failure rate, radiologic at 6 mo, costs.Sixty children recruited. two...
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, Novel Antidote the Anticoagulation Effects of Factor Inhibitors) was multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet in patients with acute major bleeding. The results final analyses are presented. Methods: Patients bleeding within 18 hours inhibitor administration were enrolled. Co-primary end points anti-FXa...
BackgroundInflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of events.MethodsIn this multicenter trial a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either or placebo and spironolactone placebo. The results are reported here. primary efficacy outcome was composite death causes, recurrent infarction, stroke, unplanned ischemia-driven coronary revascularization,...
We performed a double-blind randomized trial comparing high doses of subcutaneous heparin (12,500 units every 12 hours) with low (5000 for 10 days in the prevention left ventricular mural thrombosis 221 patients acute anterior myocardial infarction. Left was observed by two-dimensional echocardiography on 10th day after infarction 95 (11 percent) high-dose group and 28 88 (32 low-dose (P = 0.0004). One patient four had nonhemorrhagic strokes 0.17). fatal pulmonary embolism. There no...
Investigations with in vitro and animal models suggest an interaction between amiodarone beta-blockers. The objective of this work was to explore if beta-blocker treatment plays a role the decrease cardiac arrhythmic deaths patients recovered from acute myocardial infarction. A pooled database 2 similar randomized clinical trials, European Amiodarone Myocardial Infarction Trial (EMIAT) Canadian (CAMIAT), used. Four groups post-myocardial infarction were defined: beta-blockers used, used...
In a multicenter trial of aspirin or sulfinpyrazone in the treatment unstable angina, we examined possible importance to outcome mentioning potential side effects consent form. Inclusion, two three centers, statement outlining gastrointestinal resulted sixfold increase (P < 0.001) number subjects these centers withdrawing from study because subjective, minor symptoms. Major complications such as peptic ulcer bleeding diagnosed by physicians were similar centers. Furthermore, no patient...